Peptide Libraray

TG20

General Information

DRACP ID DRACP01829

Peptide Name TG20

Sequence NHFTLKCPKTALTEPPTLAY

Sequence Length 20

UniProt ID P13664

PubChem CID Not available

Origin Derived from the SAG1 surface protein from the parasite Toxoplasma gondii

Type Synthetic peptide

Classification

Active ACP

Activity Information

Cell Line	Disease	Cancer Classified	Activity	Assay	Testing Time	Literature
COLO 205	Colon adenocarcinoma	Carcinoma	<5% cytotoxicity at 1 µM	MTT assay	24 h	Patent
COLO 205	Colon adenocarcinoma	Carcinoma	<20% cytotoxicity at 10 µM	MTT assay	24 h	Patent
COLO 205	Colon adenocarcinoma	Carcinoma	~15% cytotoxicity at 1 µM	MTT assay	48 h	Patent
COLO 205	Colon adenocarcinoma	Carcinoma	>20% cytotoxicity at 10 µM	MTT assay	48 h	Patent
COLO 205	Colon adenocarcinoma	Carcinoma	<5% cytotoxicity at 1 µM	MTT assay	72 h	Patent
COLO 205	Colon adenocarcinoma	Carcinoma	<5% cytotoxicity at 10 µM	MTT assay	72 h	Patent
UM-UC-3	Bladder carcinoma	Carcinoma	10% cytotoxicity at 1 µM	MTT assay	24 h	Patent
UM-UC-3	Bladder carcinoma	Carcinoma	<10% cytotoxicity at 10 µM	MTT assay	24 h	Patent
UM-UC-3	Bladder carcinoma	Carcinoma	~25% cytotoxicity at 1 µM	MTT assay	48 h	Patent
UM-UC-3	Bladder carcinoma	Carcinoma	<25% cytotoxicity at 10 µM	MTT assay	48 h	Patent
UM-UC-3	Bladder carcinoma	Carcinoma	~45% cytotoxicity at 1 µM	MTT assay	72 h	Patent
UM-UC-3	Bladder carcinoma	Carcinoma	<45% cytotoxicity at 10 µM	MTT assay	72 h	Patent
HCT 116	Colon carcinoma	Carcinoma	20% cytotoxicity at 1 µM	MTT assay	24 h	Patent
HCT 116	Colon carcinoma	Carcinoma	10% cytotoxicity at 10 µM	MTT assay	24 h	Patent
HCT 116	Colon carcinoma	Carcinoma	<5% cytotoxicity at 1 µM	MTT assay	48 h	Patent
HCT 116	Colon carcinoma	Carcinoma	<3% cytotoxicity at 10 µM	MTT assay	48 h	Patent
HCT 116	Colon carcinoma	Carcinoma	<20% cytotoxicity at 1 µM	MTT assay	72 h	Patent
HCT 116	Colon carcinoma	Carcinoma	15% cytotoxicity at 10 µM	MTT assay	72 h	Patent
SiHa	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	~15% cytotoxicity at 1 µM	MTT assay	24 h	Patent
SiHa	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	5% cytotoxicity at 10 µM	MTT assay	24 h	Patent
SiHa	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	10% cytotoxicity at 1 µM	MTT assay	48 h	Patent
SiHa	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	<10% cytotoxicity at 10 µM	MTT assay	48 h	Patent
SiHa	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	<20% cytotoxicity at 1 µM	MTT assay	72 h	Patent
SiHa	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	20% cytotoxicity at 10 µM	MTT assay	72 h	Patent
Ca Ski	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	~15% cytotoxicity at 1 µM	MTT assay	24 h	Patent
Ca Ski	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	~5% cytotoxicity at 10 µM	MTT assay	24 h	Patent
Ca Ski	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	~10% cytotoxicity at 1 µM	MTT assay	48 h	Patent
Ca Ski	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	<10% cytotoxicity at 10 µM	MTT assay	48 h	Patent
Ca Ski	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	<20% cytotoxicity at 1 µM	MTT assay	72 h	Patent
Ca Ski	Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri	Carcinoma	20% cytotoxicity at 10 µM	MTT assay	72 h	Patent
HTB-9(5637)	Bladder carcinoma	Carcinoma	20% cytotoxicity at 1 µM	MTT assay	24 h	Patent
HTB-9(5637)	Bladder carcinoma	Carcinoma	~10% cytotoxicity at 10 µM	MTT assay	24 h	Patent
HTB-9(5637)	Bladder carcinoma	Carcinoma	<5% cytotoxicity at 1 µM	MTT assay	48 h	Patent
HTB-9(5637)	Bladder carcinoma	Carcinoma	<3% cytotoxicity at 10 µM	MTT assay	48 h	Patent
HTB-9(5637)	Bladder carcinoma	Carcinoma	<20% cytotoxicity at 1 µM	MTT assay	72 h	Patent
HTB-9(5637)	Bladder carcinoma	Carcinoma	~15% cytotoxicity at 10 µM	MTT assay	72 h	Patent

Hemolytic Activity Not available

Normal (non-cancerous) Cytotoxicity Not available

Target Not available

Affinity Not available

Mechanism Not available

Nature Anticancer

Structure Information

PDB ID Not available

Predicted Structure DRACP01829

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Chiral L

Physicochemical Information

Formula C103H161N25O29S

Absent amino acids DGIMQRSVW

Common amino acids T

Mass 258470

Pl 8.53

Basic residues 3

Acidic residues 1

Hydrophobic residues 6

Net charge 2

Boman Index -1699

Hydrophobicity -33

Aliphatic Index 68.5

Half Life
Mammalian: 30 hour
Yeast: >20 hour
E.coli: >10 hour

Extinction Coefficient cystines 1490

Absorbance 280nm 78.42

Polar residues 7

Amino acid distribution

Literature Information

Literature 1

Pubmed ID Not available

Title Not available

Doi Not available

Year Not available

Patent

Patent ID WO2012042540A2

Patent Title Anticancer Agent

Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: JP, US, WO, EP; Legal Status: Pending; Application No: 2011000680; Filed: Sep 30, 2011; Published: Apr 5, 2012; Earliest Priority: Oct 1, 2010

Other Published ID WO2012042540A9 EP2621510A2 EP2621510A4 JP2013543493A JP5873499B2 US2014051643A1 US9624277B2